Ken Griffin Prelude Therapeutics Inc Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$2.07 - $6.37 $206 - $637	100 Added 25.0%	500 $1,000
Q2 2024 Aug 14, 2024	BUY	$3.32 - $5.63 $664 - $1,126	200 Added 100.0%	400 $1,000
Q1 2024 May 15, 2024	SELL	$2.68 - $4.84 $1,340 - $2,420	-500 Reduced 71.43%	200 $0
Q4 2023 Feb 14, 2024	BUY	$1.69 - $4.37 $845 - $2,185	500 Added 250.0%	700 $2,000
Q3 2023 Nov 14, 2023	SELL	$2.74 - $4.79 $822 - $1,437	-300 Reduced 60.0%	200 $0
Q2 2023 Aug 14, 2023	BUY	$4.45 - $8.12 $2,225 - $4,059	500 New	500 $2,000
Q4 2022 Feb 14, 2023	SELL	$4.61 - $8.5 $668,911 - $1.23 Million	-145,100 Reduced 99.93%	100 $0
Q3 2022 Nov 14, 2022	SELL	$5.0 - $8.82 $760,000 - $1.34 Million	-152,000 Reduced 51.14%	145,200 $960,000

35.7M

500

300

Ticker PRLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,369,200
Market Cap $37.8M
Description
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.